Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Asia Healthcare Industry Digest.
Press releases published on April 3, 2025
aTyr Pharma to Participate in April Investor Conferences
GlobeNewswire
·
April 3, 2025
SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that …
electroCore Named One of The Americas’ Fastest Growing Companies by the Financial Times
GlobeNewswire
·
April 3, 2025
ROCKAWAY, N.J., April 03, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, has been recognized by the Financial Times as one of “The Americas’ Fastest Growing Companies 2025.” …
Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-1301
GlobeNewswire
·
April 3, 2025
KANSAS CITY, Kan., April 03, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation …
Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis
GlobeNewswire
·
April 3, 2025
Temporomandibular joint (TMJ) osteoarthritis is a degenerative, debilitating and progressive disease, the second most common musculoskeletal condition affecting five to 12% of the population globally TMJ causes pain and stiffness in the jaw, making it …
Greenwich LifeSciences Provides Global Update on FLAMINGO-01
GlobeNewswire
·
April 3, 2025
STAFFORD, Texas, April 03, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy …
Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting
GlobeNewswire
·
April 3, 2025
MELBOURNE, Australia and SAN FRANCISCO, April 03, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative …
Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics
GlobeNewswire
·
April 3, 2025
Jonathan McNeill, M.D., Appointed President and Chief Operating Officer Ellie Im, M.D., Appointed Chief Medical Officer Additional Leadership Appointments: Rick Scalzo, MBA, as Chief Financial Officer, and Amy Reilly, as Chief Communications Officer Team …
Aveanna Healthcare Holdings Announces Agreement to Acquire Thrive Skilled Pediatric Care
GlobeNewswire
·
April 3, 2025
ATLANTA, April 03, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced that it has entered into …
Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy
GlobeNewswire
·
April 3, 2025
CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the first patient has been dosed …
Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)
GlobeNewswire
·
April 3, 2025
NEW YORK and MELBOURNE, Australia, April 03, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing new oral combination medicines, today announced that the …
Minovia Therapeutics Announces FDA Clearance of Second IND Application, for a Phase II Clinical Trial of Lead Product MNV-201 in Pearson Syndrome
GlobeNewswire
·
April 3, 2025
MNV-201 is Minovia’s second generation mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with allogeneic mitochondria Rare Pediatric Designation granted MNV-201 is also being studied in a Phase Ib for low-risk …
MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates
GlobeNewswire
·
April 3, 2025
Agreement with Hercules Capital significantly increases financial and operational strength, provides up to $500 million in capital with no dilution to shareholders, an attractive cost of capital and low operational and strategic incumbrances, and sets a …
Boundless Bio to Participate in the Needham Virtual Healthcare Conference
GlobeNewswire
·
April 3, 2025
SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified …
Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences’ DecisionDx®-Melanoma Test
GlobeNewswire
·
April 3, 2025
Consistent with prior studies, published results from Castle’s DECIDE study show DecisionDx-Melanoma can both accurately identify patients with less than 5% risk of sentinel lymph node (SLN) positivity, who can safely consider forgoing the sentinel lymph …
Auron Presents New Preclinical Data for AUTX-703 in Small Cell Lung Cancer (SCLC)
GlobeNewswire
·
April 3, 2025
NEWTON, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced data from a poster presentation …
Breaking News: Early Clinical Trial on Plant-Based Finasteride Alternative Shows Exciting Results Amid Growing Concerns Over Drug Side Effects
GlobeNewswire
·
April 3, 2025
CLEVELAND, April 03, 2025 (GLOBE NEWSWIRE) -- The hair loss industry is at a tipping point. A recent Wall Street Journal exposé has reignited concerns about the severe and long-term side effects of finasteride, the FDA-approved drug for male pattern …
Ligandrol (LGD-4033) SARMs: Ligandrol Benefits, Ligandrol Results & Buy Ligandrol Pills Alternatives Ligan 4033 By CrazyBulk
GlobeNewswire
·
April 3, 2025
NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- “We’ve got several pro bodybuilding athletes ready and waiting to get to know you in our free private CrazyBulk community. And you’ll receive an invite to it the minute you purchase any CrazyBulk product. These …
Sai Life Sciences sets up Peptide Research Center in India
GlobeNewswire
·
April 3, 2025
HYDERABAD, India, April 03, 2025 (GLOBE NEWSWIRE) -- Sai Life Sciences Limited (BSE: 544306 I NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), has inaugurated a dedicated Peptide Research Center at …
Arialief: We Tested It—Here’s Our Honest Arialief Review “Shocking Conclusion”
GlobeNewswire
·
April 3, 2025
AURORA, Colo., April 03, 2025 (GLOBE NEWSWIRE) -- Arialief caught my attention from the very first day I heard about it. It’s not every day I commit to testing a new supplement for over three months and then share my personal journey. As someone who has …
Prime Biome: We Tested It—Here’s My Honest Prime Biome Review After 117 Days!
GlobeNewswire
·
April 3, 2025
ST. PETERSBURG, Fla., April 03, 2025 (GLOBE NEWSWIRE) -- Prime Biome caught my attention the very first day I heard about it. It’s not every day that I commit to a new supplement for nearly four months and then share my entire journey. But after …